This information is intended for use by health professionals

1. Name of the medicinal product

Argatroban 1 mg/ml Solution for Infusion.

2. Qualitative and quantitative composition

1 ml solution for infusion contains 0.966 mg of argatroban equivalent to 1 mg argatroban monohydrate.

1 Vial with 50 ml solution for infusion contains 48.30 mg of argatroban equivalent to 50 mg argatroban monohydrate.

Excipient with known effect: This medicinal product contains 3.54 mg of sodium per ml solution. For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for Infusion.

Clear colourless to pale yellow solution.

4. Clinical particulars
4.1 Therapeutic indications

Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.

The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.

4.2 Posology and method of administration

Initial Dosage

Treatment with Argatroban should be initiated under the guidance of a physician with experience in coagulation disorders.

The initial dosage in adult patients without hepatic impairment in HIT type II is 2 microgram/kg/min, administered as a continuous infusion (see Method of Administration). Before Argatroban is administered, heparin therapy should be discontinued and a baseline aPTT value obtained.

Paediatric population

Currently available data are described in section 5.2, but no recommendation on a posology can be made.

Standard recommendations

Monitoring:

In general, therapy with Argatroban is monitored using the activated partial thromboplastin time (aPTT).

Tests of anticoagulant effects (including the aPTT) attain steady-state levels typically within 1-3 hours following initiation of Argatroban .

The target range for steady-state aPTT is 1.5-3.0 times the initial baseline value, but not exceeding 100 seconds.

Dose adjustment may be required to attain the target aPTT (see Dose Modifications). aPTT should be checked two hours after the start of the infusion to confirm that the aPTT is within the desired therapeutic range. Thereafter, the aPTT should be monitored at least once per day.

Dose modifications:

After the initial dose of Argatroban, the dose can be adjusted based on the clinical course until the steady-state aPTT is within the desired therapeutic range (1.5 to 3.0 times the initial baseline value but not exceeding 100 seconds). In case of an elevated aPTT (greater than 3 times baseline or 100 seconds), the infusion should be discontinued until the aPTT is within the desired range of 1.5 to 3 times baseline (typically within 2 hours of discontinuation of infusion), and the infusion restarted at one half of the previous infusion rate. The aPTT should be checked again after 2 hours.

The maximum recommended dose is 10 microgram/kg/min. The maximum recommended duration of treatment is 14 days, although there is limited clinical experience of administration for longer periods (see section 5.1).

Standard dosing schedule

Initial Infusion Rate 2 mcg/kg/min.

Critically Ill / Hepatically impaired patients

Initial infusion rate 0.5 mcg/kg/min.

aPTT (s)

Infusion Rate change

Next aPTT

Infusion Rate change

Next aPTT

< 1.5 times baseline

Increase by 0.5 mcg/kg/min.

2 hours

Increase by 0.1 mcg/kg/min.

4 hours

1.5 - 3.0 times baseline (not exceeding 100 s)

No change

2 hours; after 2 consecutive aPTT's within target range, Check at least once per day

No change

4 hours; after 2 consecutive aPTT's within target range Check at least once per day

> 3.0 times baseline or > 100 s

Stop infusion until the aPTT is 1.5 - 3.0 times baseline; Resume at half of the previous infusion rate

2 hours

Stop infusion until the aPTT is 1.5-3.0 times baseline; Resume at half of the previous infusion rate

4 hours

Method of administration

Argatroban is supplied as a ready to use solution for infusion with concentration of 1 mg/ml (50 mg/50 ml), it does not require dilution before use.

Standard infusion rates for the 2 microgram/kg/min recommended initial dosage (1 mg/ml final concentration) are detailed in the table below. The standard infusion rates for patients with moderate hepatic impairment (Child-Pugh Class B), after cardiac surgery and critically ill patients with a starting infusion rate of 0.5 microgram/kg/min are also detailed in the table below:

Body Weight (kg)

Infusion Rate (ml/hr)

2 microgram/kg/min

0.5 microgram/kg/min

50

6

1.5

60

7

1.8

70

8

2.1

80

10

2.4

90

11

2.7

100

12

3.0

110

13

3.3

120

14

3.6

130

16

3.9

140

17

4.2

Additional Information on Special Populations:

Elderly patients

The standard initial dosage recommendations for use in adults are applicable to elderly patients.

Children and adolescents (<18 years)

Limited data from a prospective clinical study in 18 children (neonates to 16 years old) and published data is available. The safe and effective dose or the effective target range for aPTT or activated clotting time (ACT) of argatroban has not been clearly established in this patient population (see Section 5.1 and 5.2).

Renal impairment

The standard initial dosage recommendations for use in adults are applicable to patients with renal impairment (see section 5.2).

Limited data is available from the use of argatroban in haemodialysis. Based on the data, therapy could be initiated with an initial bolus (250 microgram/kg) followed by continuous infusion of 2 microgram/kg/min. The infusion is stopped 1 hour before the end of the procedure. The target ACT range is 170-230 seconds (measured using the Haemotec device).

In patients that are already being treated with Argatroban no bolus dose is required.

Argatroban clearance by high flux membranes used during haemodialysis and continuous venovenous haemofiltration was clinically insignificant.

Hepatic impairment

For patients with moderate hepatic impairment (Child-Pugh Class B), an initial dose of 0.5 microgram/kg/min is recommended (see section 4.4 and section 5.2). The aPTT should be monitored closely and the dosage should be adjusted as indicated clinically. Argatroban is contra-indicated in patients with severely impaired liver function.

Patients with HIT Type II after cardiac surgery and critically ill patients

Limited data is available from the use of argatroban in patients with HIT Type II after cardiac surgery and critically ill patients / intensive care unit (ICU) patients with (multiple) organ system failure. Based on the data therapy could be initiated with a starting infusion rate of 0.5 microgram/kg/min (maximum 10 microgram/kg/min) and adjusted to the target aPTT range of 1.5-3.0 times baseline value (not exceeding 100 seconds).

In critically ill/ICU patients with severe (multiple) organ failure (as assessed by SOFA-II APACHE-II or comparable scores) a reduced maintenance dose is recommended.

The clinical status of the patient, especially acute changes in hepatic function, should be taken into account and the infusion rate should be carefully adjusted to maintain the aPTT in the desired range.

An increase in the frequency of monitoring is recommended to ensure the target aPTT values are achieved and maintained.

Patients with HIT Type II undergoing percutaneous coronary intervention (PCI)

Limited data is available from the use of argatroban in patients with HIT Type II undergoing percutaneous coronary intervention. Based on the data, when there is no alternative, therapy could be initiated with a bolus dose of 350 microgram/kg over 3 to 5 minutes followed by an infusion dose of 25 microgram/kg/min. ACT should be checked 5 to 10 minutes after the bolus dose is completed. The procedure may proceed if the ACT is greater than 300 sec. If the ACT is below 300 sec, an additional bolus dose of 150 microgram/kg should be administered, the infusion rate be increased to 30 microgram/kg/min, and the ACT should be checked 5 to 10 minutes later. If the ACT is higher than 450 sec, the infusion rate should be decreased to 15 microgram/kg/min and ACT values be checked 5 to 10 min later. Once a therapeutic ACT between 300 to 450 sec has been achieved, the infusion dose should be continued for the duration of the procedure. ACT measurements were recorded using both Haemotec and Haemochrom devices.

The efficacy and safety of argatroban injection use in combination with GPIIb/IIIa inhibitors has not been established.

Body Weight (kg)

For ACT 300-450 seconds Initial Dosage 25 mcg/kg/min

If ACT <300 seconds Dosage Adjustment† 30 mcg/kg/min

If ACT >450 seconds Dosage Adjustment 15 mcg/kg/min

Bolus Dose

(mcg)

Infusion Dose

(mcg/min)

Infusion Rate

(mL/hr)

Bolus Dose

(mcg)

Infusion Dose

(mcg/min)

Infusion Rate

(mL/hr)

Infusion Dose

(mcg/min)

Infusion Rate

(mL/hr)

50

17500

1250

75

7500

1500

90

750

45

60

21000

1500

90

9000

1800

108

900

54

70

24500

1750

105

10500

2100

126

1050

63

80

28000

2000

120

12000

2400

144

1200

72

90

31500

2250

135

13500

2700

162

1350

81

100

35000

2500

150

15000

3000

180

1500

90

110

38500

2750

165

16500

3300

198

1650

99

120

42000

3000

180

18000

3600

216

1800

108

130

45500

3250

195

19500

3900

234

1950

117

140

49000

3500

210

21000

4200

252

2100

126

NOTE: 1 mg/ml = 1000 microgram (mcg)/ml

Additional IV bolus dose of 150 mcg/kg should be administered if ACT <300 seconds.

Specific dosing information on patients with hepatic impairment undergoing PCI is not available. Therefore, the use of argatroban for treatment of patients with hepatic impairment requiring PCI is not recommended.

Recommendations for use in patients scheduled for a conversion to oral anticoagulation

Use of oral anticoagulants (of the coumarin type) should be delayed until substantial resolution of thrombocytopenia (e.g. platelets >100 x 109/l) to avoid coumarin associated microvascular thrombosis and venous limb gangrene. The intended maintenance dose should be started with no loading dose.

Quick type PT assay

Owren type PT assay

In a Quick type PT assay the recommendations below should be considered:

Co-administration of Argatroban and oral anticoagulants of the coumarin type produces an additive effect on the INR when the Quick type PT assay is used.

The INR depends on both the dose of Argatroban and the International Sensitivity Index (ISI) of the thromboplastin reagent used.

In general, with doses of Argatroban up to 2 microgram/kg/min, Argatroban can be discontinued when the INR reaches up to 4 on combined therapy.

When an Owren PT type assay is used the plasma samples is considerably diluted prior to analysis and the recommendations below should be considered:

In vitro tests indicate there is no clinically significant effect of Argatroban on the INR value at a typical plasma concentration arising from a dose of around 2 microgram/kg/min. However, higher concentrations of Argatroban may result in an increase of the INR values.

The target value for INR on co- therapy should be as recommended for the oral anticoagulant alone i.e. 2-3.

For both the Quick and Owren type PT assays;

Co-therapy of Argatroban and oral anticoagulants (of the coumarin type) is recommended for a minimum of 5 days. INR should be measured daily while Argatroban and oral anticoagulants are co-administered. On co-therapy the target value for INR should be within the therapeutic range according to the type of assay used (see above) for at least 2 days before Argatroban is discontinued.

The INR measurement should be repeated 4-6 hours after discontinuation of Argatroban .If the repeat INR is below the desired therapeutic range, the infusion of Argatroban should be resumed and the procedure repeated daily until the desired therapeutic range on oral anticoagulants alone is reached.

For doses greater than 2 microgram/kg/min, the relationship between INR on oral anticoagulants alone or INR on oral anticoagulants plus Argatroban is less predictable. With such higher doses, the dose of Argatroban should be temporarily reduced to 2 microgram/kg/min in order to improve the prediction of INR on oral anticoagulants alone (see above). The INR on Argatroban and oral anticoagulants should be measured 4 to 6 hours after reduction of the Argatroban dose.

4.3 Contraindications

Argatroban is contraindicated in patients with uncontrolled bleeding. Hypersensitivity to argatroban or to any of the excipients. Severe hepatic impairment.

4.4 Special warnings and precautions for use

Argatroban causes a generally increased tendency to bleeding. An unexplained fall in haematocrit, fall in blood pressure, or any other unexplained symptom should lead to consideration of a haemorrhagic event.

Argatroban should be used with extreme caution in disease states and other circumstances in which there is an increased danger of hemorrhage. These include treatment for severe hypertension; diabetic retinopathy; immediately following lumbar puncture; spinal anesthesia; major surgery, especially involving the brain, spinal cord, or eye; hematological conditions associated with increased bleeding tendencies such as congenital or acquired bleeding disorders and gastrointestinal lesions such as ulcerations.

Parenteral anticoagulants: All parenteral anticoagulants should be discontinued before administration of Argatroban . When Argatroban is to be started after cessation of heparin therapy, sufficient time should be allowed for the effect of heparin on the aPTT to decrease prior to start of Argatroban therapy (about 1-2 hours).

Hepatic Impairment: Caution should be exercised when administering Argatroban to patients with hepatic disease, by starting with a lower dose and carefully titrating until the desired level of anticoagulation is achieved (see section 4.2). Also, upon cessation of Argatroban infusion in the hepatically-impaired patient, full reversal of anticoagulant effects may require longer than 4 hours due to decreased clearance of argatroban.

Laboratory Tests: Measurements of aPTT are recommended for monitoring the infusion. Although other plasma coagulation tests including prothrombin time (PT, expressed for example as the International Normalized Ratio (INR)), the activated clotting time (ACT) and thrombin time (TT) are affected by Argatroban; the therapeutic ranges for these tests have not been defined. Plasma argatroban concentrations also correlate well with the anticoagulant effects.

The concomitant use of Argatroban and oral anticoagulants may result in prolongation of the PT (INR) beyond that produced by oral anticoagulants alone. Refer to section 4.2 for alternative approaches for monitoring concurrent Argatroban and oral anticoagulants therapy.

This medicinal product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not use this medicinal product.

There is no specific antidote to Argatroban.

4.5 Interaction with other medicinal products and other forms of interaction

Concomitant use with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.

Oral anticoagulant agents: Pharmacokinetic drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in an increase of the International Normalized Ratio (INR). Refer to section 4.2 for recommendations for managing the switch from Argatroban to oral anticoagulation.

Thrombolytics, anti-platelet and other agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.

The risks for interaction with argatroban have not been evaluated. Caution is needed when concomitant medicinal products are commenced.

4.6 Fertility, pregnancy and lactation

Pregnancy:

There are no adequate data from the use of Argatroban in pregnant women. The effect of argatroban on reproduction has been incompletely studied in animal experiments, as technical issues have limited systemic exposure (see section 5.3 for results of animal studies). The increased bleeding risk with Argatroban may constitute a risk in treatment during pregnancy. Argatroban should be used during pregnancy only if treatment is clearly necessary.

Breast-feeding:

Information concerning the passage of argatroban into human milk is not available. Animal studies using radiolabelled argatroban have shown that radioactivity reaches greater levels in breast milk than in maternal blood. Breast feeding is not recommended during treatment.

Fertility:

Animal studies do not indicate effects of argatroban on fertility (see section 5.3). There are no data on the effects on human fertility.

4.7 Effects on ability to drive and use machines

The effect of treatment with Argatroban on patient's ability to drive or operate machinery has not been evaluated.

4.8 Undesirable effects

Bleeding complications, as is to be expected given the pharmacological properties, constitute the main adverse events. In the clinical trials involving patients with HIT type II anticoagulated with Argatroban, the incidence of major bleeds was 31/568 (5.5%) and minor bleeds 221/568 (38.9%). The incidence of major bleeds was almost three times higher in those patients in whom the aPTT level exceeded more than three times the baseline value than in those whose aPTT was within the therapeutic range. Dosage of Argatroban should be adjusted to achieve a target aPTT level of 1.5-3.0 x baseline not exceeding 100 seconds (see section 4.2).

The incidence of adverse reactions in clinical trials (568 patients with HIT Type II) which are considered to be possibly related to Argatroban is stated below.

Organ system

Common (≥1/100, ≤1/10)

Uncommon (≥1/1000, ≤1/100)

Infections and infestations

Infection, urinary tract infection

Blood and lymphatic system disorders

Anaemia

Coagulopathy, thrombocytopenia, leukopenia

Metabolism and nutrition disorders

Anorexia, hypoglycaemia, hyponatraemia

Psychiatric disorders

Confusional state

Nervous system disorders

Dizziness, headache, syncope, cerebrovascular accident, hypotonia, speech disorder

Eye disorders

Visual disturbance

Ear and labyrinth disorders

Deafness

Cardiac disorders

Atrial fibrillation, tachycardia, cardiac arrest, myocardial infarction, arrhythmia, supraventricular, pericardial effusion, ventricular tachycardia, hypertension, hypotension

Vascular disorders

Deep vein thrombosis, haemorrhage

thrombosis, phlebitis, thrombophlebitis, thrombophlebitis leg superficial, shock, peripheral ischaemia, peripheral embolism

Respiratory,thoracic and mediastinal disorders

Hypoxia, pulmonary embolism, dyspnoea, pulmonary haemorrhage, pleural effusion, hiccups

Gastrointestinal disorders

Nausea

Vomiting, constipation, diarrhoea, gastritis, gastrointestinal haemorrhage, melaena, dysphagia, tongue disorder

Hepatobiliary disorders

Hepatic function abnormal, hyperbilirubinaemia, hepatic failure, hepatomegaly, jaundice

Skin and subcutaneous tissue disorders

Purpura

Rash, sweating increased, dermatitis bullous, alopecia, skin disorder, urticaria

Musculoskeletal and connective tissue disorders

Muscular weakness, myalgia

Renal and urinary disorders

Haematuria, renal insufficiency

General disorders and administration site conditions

Pyrexia, pain, fatigue, application site reaction, injection site reaction, oedema peripheral

Investigations

Prothrombin complex level decreased, coagulation factor decreased, coagulation time prolonged, aspartate aminotransferase increased, alanine aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased

Injury and poisoning and procedural complications

Wound secretion

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard

4.9 Overdose

Excessive anticoagulation, with or without bleeding, may be controlled by discontinuing Argatroban or by decreasing the infusion rate. In clinical studies, anticoagulation parameters return to baseline generally within 2 to 4 hours after discontinuation of Argatroban. Reversal of anticoagulant effect may take longer in patients with hepatic impairment.

No specific antidote to Argatroban is available. If life-threatening bleeding occurs and excessive plasma levels of argatroban are suspected, Argatroban should be discontinued immediately and aPTT and other coagulation tests should be performed. Symptomatic and supportive therapy should be provided to the patient.

Lethal single intravenous doses of argatroban for mice, rats, rabbits, and dogs were 200, 124, 150, and 200 mg/kg respectively. The symptoms of acute toxicity were loss of righting reflex, tremors, clonic convulsions, paralysis of hind limbs, and coma.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct thrombin inhibitors.

ATC code: B01AE03.

Argatroban, a synthetic L-arginine derivative, is a direct thrombin inhibitor (molecular weight 526.65) that binds reversibly to thrombin. Argatroban exerts its anticoagulant effect independently of antithrombin III and inhibits fibrin formation; activation of coagulation factors V, VIII and XIII; activation of protein C; and platelet aggregation.

Argatroban is highly selective for thrombin; inhibitory constant (Ki) values in studies in vitro with synthetic tripeptides ranged from 5 to 39 nM.

Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. It does not interact with heparin induced antibodies. There was no evidence of formation of antibodies against argatroban in patients who received multiple doses of argatroban.

Evidence of the efficacy of argatroban in HIT type II derives from data from two studies where a total of 568 adult patients were treated with argatroban. The average treatment duration employed in these clinical studies was 6 days with a maximum of 14 days. In the first prospective trial, an improvement in the composite outcome at 37 days (death, amputation, new thrombosis) was observed in the argatroban group versus the historical controls (n=46) The reduction of the incidence of the primary endpoint was consistent in the subgroups of patients having HIT type II without thromboembolic complications (25.6% vs 38.8%), p=0.014 by categorical analysis; p=0.007 by time-to-event analysis) and HIT type II with thromboembolic complications (43.8% vs 56.5%, p=0.131 by categorical analysis; p=0.018 by time to event analysis).

The studies were not statistically powered for individual endpoints. However, in the first prospective study, the reduction of the incidence of individual endpoints for patients having HIT type II without and with thromboembolic complications respectively was as follows: mortality (16.9 vs 21.8%, n.s) and (18.1 vs 28.3%, n.s), amputation (1.9 vs 2.0%, n.s) and (11.1 vs 8.7%, n.s), new thromboses (6.9 vs 15%, p=0.027) and (14.6 vs 19.6%, n.s).

In the second follow-on study, similar outcomes were observed.

The efficacy and safety of the use of argatroban in patients under 18 years of age has not been established. However, limited results from a prospective clinical study conducted in the USA in 18 seriously ill paediatric patients with (suspected) HIT Type II requiring an alternative to heparin anticoagulation are available.

The age range of the patients participating in this study was less than six months (8 patients), six months to less than 8 years (6 patients) and 8 to 16 years (4 patients). All patients had serious underlying conditions and were receiving multiple concomitant medications.

Thirteen patients received argatroban solely as a continuous infusion (no bolus dose). In the majority of these 13 patients dosing was initiated at 1 microgram/kg/min to achieve an aPTT of 1.5 to 3 times the baseline value (not exceeding 100 seconds). Most patients required multiple dose adjustments to maintain anticoagulation parameters within the desired range.

During the 30 day study period thrombotic events occurred during argatroban administration in two patients and following argatroban discontinuation in three other patients. Major bleeding occurred among two patients; one patient experienced an intracranial hemorrhage after 4 days of argatroban therapy in the setting of sepsis and thrombocytopenia. Another patient completed 14 days of treatment but experienced an intracranial hemorrhage while receiving argatroban following completion of the study treatment period.

As only limited data is available, an initial continuous infusion rate of 0.75 microgram/kg/min has been suggested in seriously ill paediatric patients with normal hepatic function. A reduced starting dose of 0.2 microgram/kg/min would be suggested in seriously ill paediatric patients with impaired hepatic function (see Section 5.2). The dose adjusted to achieve target aPTT 1.5 -3 times the baseline value, not exceeding 100 seconds.

5.2 Pharmacokinetic properties

Steady-state levels of both argatroban and anticoagulant effect are typically attained within 1-3 hours and are maintained until the infusion is discontinued or the dosage adjusted. Steady-state plasma argatroban concentrations increase proportionally with dose (for infusion doses up to 40 microgram/kg/min in healthy subjects) and are well correlated with steady-state anticoagulant effects. For infusion doses up to 40 microgram/kg/min, argatroban increases, in a dose dependent fashion, the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the International Normalized Ratio (INR) and the thrombin time (TT) in healthy volunteers and cardiac patients.

Distribution

Argatroban distributes mainly in the extra-cellular fluid. The volume of distribution (Vdβ) was 391 ± 155 ml/kg (mean ± SD). Argatroban is 54% bound in human serum proteins, with binding to albumin and α1-acid glycoprotein being 20% and 34% respectively.

Metabolism

The metabolism of argatroban has not yet been fully characterized. The metabolites identified (M-1, M-2, and M-3) are formed by hydroxylation and aromatization of the 3-methyltetrahydroquinoline ring in the liver. The formation of the metabolites is catalysed in vitro by cytochrome P450 enzymes CYP3A4/5, but this is not a major path of elimination in vivo. The primary metabolite (M1) exerts 40- fold weaker antithrombin effect than argatroban. Metabolites M-1, M-2 and M-3 were detected in the urine, and M-1 was detected in plasma and faeces.

There is no interconversion of the 21-(R) and 21-(S) diastereoisomers. The ratio of diastereoisomers is unchanged by metabolism or hepatic impairment, remaining constant at 65:35 (±2%).

Excretion

On termination of the infusion, the concentration of argatroban decreased rapidly. The apparent terminal elimination half life (mean ± SD) is 52 ± 16 min. Clearance (mean ± SD) was 5.2 ± 1.3 ml/kg/min.

Argatroban is excreted mainly in the faeces, presumably through biliary secretion.

Following intravenous infusion of 14Cradiolabelled argatroban 21.8 ± 5.8% of the dose was excreted in urine and 65.4 ± 7.1% in the faeces.

Special populations

Elderly patients: clearance is approximately 15% lower than in younger persons. No age related dose adjustment is necessary.

Renal impairment: compared with patients with normal renal function (creatinine clearance ≥ 80ml/min) who had a terminal half-life of 47±22 min, patients with severely impaired renal function (creatinine clearance ≤ 29ml/min) had only slight prolongation of this value (65±35 min). No initial dose regimen adjustment with respect to renal function is necessary.

Hepatic impairment: in patients with hepatic impairment (Child Pugh score 7 to 11) clearance was 26% of that of healthy volunteers. Initial dose reduction is required in patients with moderate hepatic impairment. Argatroban is contraindicated in patients with severe hepatic impairment.

Paediatric patients: argatroban clearance is decreased in seriously ill paediatric patients. Based on population pharmacokinetic modeling, clearance in paediatric patients (0.17 L/hr/kg) was 50% lower compared to healthy adults (0.31 L/hr/kg). Population pharmacokinetic data also indicate that the infusion rate should be adjusted according to body weight.

Based on population pharmacokinetic modeling, patients with elevated bilirubin (secondary to cardiac complications or hepatic impairment) had, on average, 80% lower clearance (0.03 L/hr/kg) when compared to paediatric patients with normal bilirubin levels.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity. Toxicity studies with continuous intravenous infusions and reproduction toxicity studies using daily intravenous bolus injections achieved only limited systemic exposure to argatroban (2 times the exposure seen in humans). Although these studies do not suggest any particular risk to humans, their value is limited by the low systemic exposure realised.

6. Pharmaceutical particulars
6.1 List of excipients

Sorbitol

Sodium chloride

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Unopened vials: 2 years.

The product should be used immediately after opening.

6.4 Special precautions for storage

Do not freeze.

Keep vial in the outer carton in order to protect from light.

6.5 Nature and contents of container

Clear 50 ml type I glass vial sealed with a rubber stopper and an aluminium seal with a flip-off cap. Each vial contains 50 ml of solution for infusion.

Vials are supplied in cartons of 1, 5 or 6 vials pack. Not all pack-sizes may be marketed.

6.6 Special precautions for disposal and other handling

Argatroban is supplied as a ready to use solution for infusion with concentration of 1 mg/ml (50 mg/50 ml), it does not require dilution before use.

The vial is for single use only. The pH of the intravenous infusion solution is 3.2-7.5

Light resistant measures such as foil protection for intravenous lines are not necessary. No significant potency losses have been noted following simulated delivery of the solution through intravenous tubing.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Accord Healthcare Limited

Sage House, 319 Pinner Road,

North Harrow, Middlesex, HA1 4HF,

United Kingdom

8. Marketing authorisation number(s)

PL 20075/0486

9. Date of first authorisation/renewal of the authorisation

07/06/2017

10. Date of revision of the text

07/06/2017